Research ArticleArticle
Open Access
Development and Validation of a Self-Administered Questionnaire Measuring Essential Knowledge in Patients With Axial Spondyloarthritis
Catherine Beauvais, Bruno Pereira, Thao Pham, Christelle Sordet, Pascal Claudepierre, Françoise Fayet, Daniel Wendling, Félicie Costantino, Laurence Carton, Laurent Grange, Martin Soubrier, Nathalie Legoupil, Aleth Perdriger, Isabel Tavares, Emmanuelle Dernis, Laure Gossec and Malory Rodère
The Journal of Rheumatology July 2022, jrheum.211314; DOI: https://doi.org/10.3899/jrheum.211314
Catherine Beauvais
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Bruno Pereira
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Thao Pham
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Christelle Sordet
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Pascal Claudepierre
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Françoise Fayet
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Daniel Wendling
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Félicie Costantino
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Laurence Carton
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Laurent Grange
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Martin Soubrier
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Nathalie Legoupil
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Aleth Perdriger
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Isabel Tavares
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Emmanuelle Dernis
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Laure Gossec
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Malory Rodère
The study was supported by an institutional grant from the University Hospital of Clermont-Ferrand (Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; reference AOI RODERE 2016). C. Beauvais, MD, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, Paris; 2. Pereira, PhD, Département de Biostatistique Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; T. Pham, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Sainte Marguerite, Université Aix Marseille, Marseille; C. Sordet, MD, PhD, Service de Rhumatologie, Hôpitaux Universitaires Strasbourg, Strasbourg; P. Claudepierre, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Henri Mondor, AP-HP, Université Créteil, Paris; F. Fayet, BSc, M. Soubrier, MD, PhD, M. Rodère, BSc, Service de Rhumatologie, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand; D. Wendling, MD, PhD, Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon, and EA 4266 EPILAB, Université Bourgogne Franche-Comté, Besançon; F. Costantino, MD, PhD, Service de Rhumatologie, Hôpital Universitaire Ambroise Paré, AP-HP, Université Paris Saclay, Boulogne-Billancourt; L. Carton, Association AFLAR (Association Française de Lutte Anti-Rhumatismale), Paris; L. Grange, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire Grenoble Alpes, Echirolles; N. Legoupil, MD, Service de Rhumatologie, Centre Hospitalier Universitaire Cochin, AP-HP, Paris; A. Perdriger, MD, PhD, Service de Rhumatologie, Centre Hospitalier Universitaire, Rennes; I. Tavares, Service de Rééducation, Hôpital Universitaire Montpellier, Montpellier; E. Dernis, MD, MSc, Service de Rhumatologie, Hôpital Le Mans, Le Mans; L. Gossec, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, and Service de Rhumatologie, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université AP-HP, Paris France. CB has received research grants from BMS, Fresenius Kabi, Eli Lilly, and Mylan; advisory board fees from Novartis and Sandoz; and speaker fees from BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. TP has received speaker and consulting fees from AbbVie, Amgen, Biogen, BMS, Celgene, Fresenius Kabi, Janssen, Eli Lilly, MSD, Nordic Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. CS has received consulting fees from AbbVie, UCB, Eli Lilly, Nordic Pharma, GSK, Roche Chugaï, and BMS. DW has received speaker fees from AbbVie, BMS, MSD, Pfizer, Chugaï, Nordic Pharma, UCB, Novartis, Eli Lilly, Amgen, Grunenthal, and Galapagos; advisory board fees from Novartis, Janssen, AbbVie, and Amgen; and support for attending meetings from MSD, Galapagos, Chugaï, UCB, Mylan, and Fresenius Kabi. FC has received consulting and/or speaker fees from Eli Lilly, Novartis, and UCB. LG has received research grants from Amgen, Galapagos, Janssen, Eli Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB. The remaining authors declare no conflicts of interest. Address correspondence to Dr. C. Beauvais, Service de Rhumatologie Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, AP-HP, 184 rue du Faubourg Saint Antoine, 75012 Paris, France. Email: catherine.beauvais@aphp.fr. Accepted for publication July 6, 2022.
Abstract
Objective To develop and validate a patient knowledge questionnaire regarding axial spondyloarthritis (axSpA).
Methods Knowledge considered essential for patients with axSpA was identified through Delphi rounds among rheumatologists, healthcare professionals (HCPs), and patients, then reformulated to develop the knowledge questionnaire. Cross-sectional validation was performed in 14 rheumatology departments to assess internal validity (Kuder-Richardson coefficient), external validity, acceptability, reproducibility (Lin concordance correlation coefficient), and sensitivity to change (knowledge score before vs after patient education sessions and effect size).
Results The Spondyloarthritis Knowledge Questionnaire (SPAKE) is a self-administered 42-item questionnaire with a 32-item short form, both scored 0 to 100, assessing knowledge of disease, comorbidities, pharmacological treatments, nonpharmacological treatments, self-care, and adaptive skills. In the validation study (130 patients; 67 [51.5%] male, mean age 43.5 [SD 12.9] yrs), the mean (SD) score of the long-form questionnaire was 71.6 (15.4), with higher scores (better knowledge) in nonpharmacological treatments and adaptive skills and lower scores in cardiovascular comorbidity and pharmacological treatments. Acceptability was good, with no missing data; the internal validity coefficient was 0.85. Reproducibility was good (0.81, 95% CI 0.72-0.89). SPAKE showed good sensitivity to change; scores were 69.2 (15.3) then 82.7 (14.0) after patient education sessions (Hedges effect size = 0.92, 95% CI 0.52-1.31).
Conclusion SPAKE is a knowledge questionnaire for patients with axSpA, developed with the involvement of HCPs and patients and reflecting current recommendations for the management of axSpA. SPAKE will be useful in assessing knowledge acquisition and self-management strategies in routine care and research.
In this issue
The Journal of Rheumatology
Vol. 50, Issue 1
1 Jan 2023
Development and Validation of a Self-Administered Questionnaire Measuring Essential Knowledge in Patients With Axial Spondyloarthritis
Catherine Beauvais, Bruno Pereira, Thao Pham, Christelle Sordet, Pascal Claudepierre, Françoise Fayet, Daniel Wendling, Félicie Costantino, Laurence Carton, Laurent Grange, Martin Soubrier, Nathalie Legoupil, Aleth Perdriger, Isabel Tavares, Emmanuelle Dernis, Laure Gossec, Malory Rodère
The Journal of Rheumatology Jul 2022, jrheum.211314; DOI: 10.3899/jrheum.211314
Development and Validation of a Self-Administered Questionnaire Measuring Essential Knowledge in Patients With Axial Spondyloarthritis
Catherine Beauvais, Bruno Pereira, Thao Pham, Christelle Sordet, Pascal Claudepierre, Françoise Fayet, Daniel Wendling, Félicie Costantino, Laurence Carton, Laurent Grange, Martin Soubrier, Nathalie Legoupil, Aleth Perdriger, Isabel Tavares, Emmanuelle Dernis, Laure Gossec, Malory Rodère
The Journal of Rheumatology Jul 2022, jrheum.211314; DOI: 10.3899/jrheum.211314
